Cannabidiol for Health & Longevity - Quick Reference Sheet

Cannabidiol for Health & Longevity

Created on 07/17/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A non-intoxicating cannabis compound that acts on the body's stress, pain, and inflammation signaling. Its one proven effect is reducing seizures in rare, severe epilepsy. For calmer anxiety, better sleep, and everyday aches the evidence is mixed. Generally safe at consumer doses, but high doses can strain the liver and alter levels of other medicines. Many products are mislabeled. (Full Review)

Protocol

Starting Dose
10–25 mg
Once or twice daily; titrate up every 1–2 weeks
Wellness Range
25–75 mg/day
Higher regimens reserved for clinical use under supervision
Timing
Daytime or pre-bed
Daytime for anxiety; 30–60 min before bed for sleep. Take with food
Time to effect
Acute Anxiety
30–90 min
After a single oral dose
Sleep & Mood
1–2 weeks
Judged after consistent daily use
Steady State
Several days
Accumulates with repeated dosing

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Moderate-to-severe liver impairment (Child-Pugh B or C)
  • Narrow-therapeutic-index drugs without medical supervision
Key Interactions
  • Anti-seizure medications (clobazam, valproate)
  • Blood thinners and CYP2C9 substrates (warfarin)
  • CYP3A4 substrates (simvastatin, calcium-channel blockers, benzodiazepines, tacrolimus)
  • CYP2C19 substrates (citalopram, omeprazole)
  • Over-the-counter medications (diphenhydramine, melatonin, dextromethorphan)
  • Supplement interactions (St. John's Wort, grapefruit, sedating botanicals)
  • Additive-effect supplements (melatonin, valerian, kava, magnesium, high-dose ashwagandha)
  • Other interventions (alcohol, cannabis containing THC)

Risk & Side Effects

  • High: Hepatocellular injury, drug–drug interactions, somnolence and sedation, gastrointestinal effects
  • Medium: Product mislabeling and contamination
  • Low: [risks_low]
  • Speculative: Possible male reproductive effects, unknown long-term effects of chronic use

Monitoring

Marker Target Why
ALT 10–25 U/L Primary marker of liver-cell stress from cannabidiol
AST 10–25 U/L Complements ALT to confirm liver involvement
GGT 10–30 U/L Sensitive to hepatic and oxidative/detoxification stress
Total bilirubin 0.3–1.2 mg/dL Reflects overall liver clearance function
INR Per indication (only if on warfarin) Detects increased bleeding risk from raised warfarin levels

Cadence: Baseline, then ~1 and 3 months after starting or a dose increase, then every 6–12 months

Qualitative Assessment

  • Sleep quality: ease of falling asleep, night wakings, morning refreshment
  • Daytime anxiety and stress reactivity: subjective calm and resilience
  • Energy and sedation: whether daytime alertness is maintained or dulled
  • Cognitive clarity: focus and mental sharpness, watching for fogginess
  • Pain and recovery: perceived aches and post-exercise recovery